Sinoway Industrial Co., Ltd.

Apixaban 503612-47-3 Apixaban 503612-47-3

Apixaban 503612-47-3
Related Products
  • NanoActive alpha lipoic acid (ALA) 1077-28-7

    1.Basic information of NanoActive alpha lipoic acidProduct Name: NanoActive alpha lipoic acid (ALA)Other Names: NanoActive THIOOCTIC ACIDAppearance: yellow, viscous and transparent liquidTest Method: ...

  • NanoActive Astaxanthin 472-61-7

    1.Basic information of NanoActive AstaxanthinProduct Name: NanoActive AstaxanthinOther Names: NanoActive AstaAppearance: reddish to dark red, viscous and transparent liquidTest Method: HPLCCAS NO.: 47...

  • NanoActive Curcumin 458-37-7

    1.Basic information of NanoActive CurcuminProduct Name: NanoActive CurcuminOther Names: NanoActive turmeric extractAppearance: yellow, viscous and transparent liquidTest Method: HPLCCAS NO.: 458-37-7S...

Basic information of Apixaban :

Name

Apixaban

Alias

1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide

CAS NO.

503612-47-3

Molecular Formula

C25H25N5O4

Molecular Weight

459.504

EINECS

1308068-626-2

Brief Introduction

Apixaban is a novel, oral, reversible, highly selective, direct Factor Xa inhibitor developed by Pfizer and Bristol-Myers Squibb.

Storage condition

Room temperature, seal.


Use of Apixaban:

The results of the study show that compared with traditional anticoagulants, Apixaban is more effective and does not increase or decrease the risk of bleeding. Currently, the US FDA and the European EMA have approved Apixaban for prevention of venous thromboembolism (also known as venous thromboembolism or VTE) in adults undergoing total hip or total knee arthroplasty to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation ( Also known as atrial fibrillation stroke), treatment of deep vein thromboembolism (also known as deep vein thrombosis or DVT) and pulmonary embolism (also known as PE), and prevention of recurrence of DVT and PE.

COA of Apixaban :


Apixaban 503612-47-3


  • Donepezil Hydrochloride 110119-84-1&120011-70-3
    Basic information of Donepezil hydrochlorideNameDonepezil hydrochloride AliasDonepezilHCLCAS NO.120011-70-3 /110119-84-1Molecular Formula C24H29NO3·HCLMolecular Weight 415.95Quality StandardGMP cert... Donepezil Hydrochloride 110119-84-1&120011-70-3
  • Gemcitabine HCL 122111-03-9
    Basic information of Gemcitabine HCL:NameGemcitabine hydrochlorideAlias2’,2’-difluorodeoxycytidinemonohydrochloride;2’-deoxy-2’,2’-difluorocytidinemonohydrochloride;2’-deoxy-2’,2’-difluoro-cyt... Gemcitabine HCL 122111-03-9
  • Tranexamic Acid 701-54-2
    Basic information of Tranexamic AcidNameTranexamic AcidAliasAmstat,4-(Aminomethyl)cyclohexanecarboxylic acidCAS NO.701-54-2Molecular Formula C8H15NO2Molecular Weight 157.21Quality StandardBP / JP / 99... Tranexamic Acid 701-54-2
  • Sitagliptin Phosphate 654671-78-0/654671-77-9
    Basic information of Sitagliptin:NameSitagliptinMolecular FormulaC16H15F6N5OMolecular Weight407.32 Quality StandardIn housePackage Size1kg/bag or according your requirementBrief IntroductionThis drug... Sitagliptin Phosphate 654671-78-0/654671-77-9

MORE_DETAIL Apixaban 503612-47-3

Basic information of Apixaban :

Name

Apixaban

Alias

1-(4-Methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide

CAS NO.

503612-47-3

Molecular Formula

C25H25N5O4

Molecular Weight

459.504

EINECS

1308068-626-2

Brief Introduction

Apixaban is a novel, oral, reversible, highly selective, direct Factor Xa inhibitor developed by Pfizer and Bristol-Myers Squibb.

Storage condition

Room temperature, seal.


Use of Apixaban:

The results of the study show that compared with traditional anticoagulants, Apixaban is more effective and does not increase or decrease the risk of bleeding. Currently, the US FDA and the European EMA have approved Apixaban for prevention of venous thromboembolism (also known as venous thromboembolism or VTE) in adults undergoing total hip or total knee arthroplasty to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation ( Also known as atrial fibrillation stroke), treatment of deep vein thromboembolism (also known as deep vein thrombosis or DVT) and pulmonary embolism (also known as PE), and prevention of recurrence of DVT and PE.

COA of Apixaban :


Apixaban 503612-47-3

Leave a Message Email Us

We will contact you within 24 hours.

  • TEL:+86-0592-5854962
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//